{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320120855552.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1021/acs.jmedchem.5b01461"}},{"identifier":{"@type":"URI","@value":"http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01461"}},{"identifier":{"@type":"URI","@value":"https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01461"}},{"identifier":{"@type":"PMID","@value":"26878082"}}],"dc:title":[{"@value":"An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy"}],"description":[{"notation":[{"@value":"Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10-15%) fatalities in 2003. The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its viral protease, SARS-CoV 3CL(pro), has been shown to be essential for replication and has hence been recognized as a potent drug target for SARS infection. Currently, there is no effective treatment for this epidemic despite the intensive research that has been undertaken since 2003 (over 3500 publications). This perspective focuses on the status of various efficacious anti-SARS-CoV 3CL(pro) chemotherapies discovered during the last 12 years (2003-2015) from all sources, including laboratory synthetic methods, natural products, and virtual screening. We describe here mainly peptidomimetic and small molecule inhibitors of SARS-CoV 3CL(pro). Attempts have been made to provide a complete description of the structural features and binding modes of these inhibitors under many conditions."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670320120855554","@type":"Researcher","foaf:name":[{"@value":"Thanigaimalai Pillaiyar"}],"jpcoar:affiliationName":[{"@value":"Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320120855553","@type":"Researcher","foaf:name":[{"@value":"Manoj Manickam"}],"jpcoar:affiliationName":[{"@value":"College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, South Korea"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320120855552","@type":"Researcher","foaf:name":[{"@value":"Vigneshwaran Namasivayam"}],"jpcoar:affiliationName":[{"@value":"Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320120855555","@type":"Researcher","foaf:name":[{"@value":"Yoshio Hayashi"}],"jpcoar:affiliationName":[{"@value":"Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320120855556","@type":"Researcher","foaf:name":[{"@value":"Sang-Hun Jung"}],"jpcoar:affiliationName":[{"@value":"College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 34134, South Korea"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00222623"},{"@type":"EISSN","@value":"15204804"}],"prism:publicationName":[{"@value":"Journal of Medicinal Chemistry"}],"dc:publisher":[{"@value":"American Chemical Society (ACS)"}],"prism:publicationDate":"2016-02-15","prism:volume":"59","prism:number":"14","prism:startingPage":"6595","prism:endingPage":"6628"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["http://pubs.acs.org/page/policy/authorchoice_termsofuse.html"],"url":[{"@id":"http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01461"},{"@id":"https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01461"}],"createdAt":"2016-02-15","modifiedAt":"2023-04-13","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Molecular%20Conformation","dc:title":"Molecular Conformation"},{"@id":"https://cir.nii.ac.jp/all?q=Small%20Molecule%20Libraries","dc:title":"Small Molecule Libraries"},{"@id":"https://cir.nii.ac.jp/all?q=Cysteine%20Endopeptidases","dc:title":"Cysteine Endopeptidases"},{"@id":"https://cir.nii.ac.jp/all?q=Structure-Activity%20Relationship","dc:title":"Structure-Activity Relationship"},{"@id":"https://cir.nii.ac.jp/all?q=Viral%20Proteins","dc:title":"Viral Proteins"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Discovery","dc:title":"Drug Discovery"},{"@id":"https://cir.nii.ac.jp/all?q=Animals","dc:title":"Animals"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Molecular%20Medicine","dc:title":"Molecular Medicine"},{"@id":"https://cir.nii.ac.jp/all?q=Protease%20Inhibitors","dc:title":"Protease Inhibitors"},{"@id":"https://cir.nii.ac.jp/all?q=Peptidomimetics","dc:title":"Peptidomimetics"},{"@id":"https://cir.nii.ac.jp/all?q=Coronavirus%203C%20Proteases","dc:title":"Coronavirus 3C Proteases"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360005516689080064","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168762591232","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298345010349824","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CLpro Main Protease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588381045639424","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sulfoquinovosyl diacylglycerol, a component of Holy Basil Ocimum tenuiflorum, inhibits the activity of the SARS-CoV-2 main protease and viral replication in vitro"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656945786624","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593757785088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening for Inhibitors of Main Protease in SARS-CoV-2: In Silico and In Vitro Approach Avoiding Peptidyl Secondary Amides"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869855128563456","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Potential of traditional medicines in alleviating COVID-19 symptoms"}]},{"@id":"https://cir.nii.ac.jp/crid/1390587903895791744","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Computational Estimation of the Residues Involved in the Emergence of Drug Resistance to the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir using a Virtual Alanine Scan"}]},{"@id":"https://cir.nii.ac.jp/crid/1880866215948282880","@type":"Dataset","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"BindingDB Entry 1401: Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Main Protease."}]},{"@id":"https://cir.nii.ac.jp/crid/1881428067623938688","@type":"Dataset","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"BindingDB Entry 50019924: Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters."}]},{"@id":"https://cir.nii.ac.jp/crid/1882553967742779776","@type":"Dataset","relationType":["isSourceOf"],"jpcoar:relatedTitle":[{"@value":"BindingDB Entry 8917: An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy."}]},{"@id":"https://cir.nii.ac.jp/crid/2050025942155225216","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Molecular mechanisms of the medicines for COVID-19"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1021/acs.jmedchem.5b01461"},{"@type":"OPENAIRE","@value":"doi_dedup___::e22c9fa383b3956265fc3f5de99d19f6"},{"@type":"CROSSREF","@value":"10.1016/j.bmc.2018.12.019_references_DOI_EKDrhVnnoMDcpGiyxfEAeSXrwF4"},{"@type":"CROSSREF","@value":"10.1021/acs.jmedchem.1c00665_references_DOI_EKDrhVnnoMDcpGiyxfEAeSXrwF4"},{"@type":"CROSSREF","@value":"10.1246/bcsj.20220179_references_DOI_EKDrhVnnoMDcpGiyxfEAeSXrwF4"},{"@type":"CROSSREF","@value":"10.3390/ph15050539_references_DOI_EKDrhVnnoMDcpGiyxfEAeSXrwF4"},{"@type":"CROSSREF","@value":"10.1273/cbij.25.90_references_DOI_EKDrhVnnoMDcpGiyxfEAeSXrwF4"},{"@type":"CROSSREF","@value":"10.1007/s11418-024-01855-6_references_DOI_EKDrhVnnoMDcpGiyxfEAeSXrwF4"},{"@type":"CROSSREF","@value":"10.1016/j.bmc.2019.115273_references_DOI_EKDrhVnnoMDcpGiyxfEAeSXrwF4"},{"@type":"CROSSREF","@value":"10.1021/acs.jcim.1c01087_references_DOI_EKDrhVnnoMDcpGiyxfEAeSXrwF4"},{"@type":"CROSSREF","@value":"10.3389/fphar.2024.1452616_references_DOI_EKDrhVnnoMDcpGiyxfEAeSXrwF4"}]}